Find and Pitch Jounalists, Get Your Story Covered

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	MHRA grants approval for bladder cancer drug erdafitinib - 8 days ago
2	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 17 days ago Interim ALIGN Data: Atrasentan Cuts Proteinuria in IgA Nephropathy - 18 days ago Alternative Pathway Inhibition Makes Good in IgA Nephropathy - 19 days ago
3	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy - 20 days ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 8 months ago Adagrasib Meets Primary Endpoint Among Individuals with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC - 8 months ago
4	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer - 24 days ago
5	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 2 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 3 months ago Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations - 12 months ago FDA OKs New Option for Advanced ROS1-Positive Lung Cancer - 12 months ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - about 1 year ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - about 1 year ago
6	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	MHRA approves Astellas’ Vyloy combination for gastric cancer - 3 months ago
7	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Accepts NDA and Priority Review Application for Vimseltinib in Tenosynovial Giant Cell Tumors - 3 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 3 months ago FDA Grants Priority Review for Asciminib for Chronic Myeloid Leukemia - 4 months ago FDA Grants Fast Track Designation to Potential Treatment for Clear Cell Renal Cell Carcinoma - 4 months ago FDA Accepts Supplemental New Drug Application for Adagrasib for Colorectal Cancer - 9 months ago FDA Grants Orphan Drug Designation to Tigilanol Tiglate for Soft Tissue Sarcoma - 9 months ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - 11 months ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - 12 months ago FDA Approves Repotrectinib for Treatment of ROS1-Positive NSCLC - 12 months ago TAK-279 Demonstrates Improvements in ACR 20 Response for Psoriatic Arthritis - about 1 year ago FDA Grants Priority Review to New Drug Application for Belzutifan for Advanced Renal Cell Carcinoma - about 1 year ago
8	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr for cGVHD - 3 months ago Embracing a Precision Medicine Approach to KRAS G12C–Mutated Advanced NSCLC With Adagrasib - 7 months ago
9	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	TIL Therapy May Offer Novel Approach for Metastatic Lung Cancer - 4 months ago Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma - 10 months ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - 12 months ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - 12 months ago New Data on TYK2 Inhibitors for Psoriasis, Psoriatic Arthritis - 12 months ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - 12 months ago
10	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 5 months ago FDA Approves New Frontline Regimen for Aggressive ALL - 8 months ago FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 9 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - 11 months ago Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia - 11 months ago Non-Covalent BTK Inhibitor Approved for CLL - 12 months ago Lymphoma Drug Copanlisib to Be Pulled From U.S. Market - about 1 year ago New Oral Drug Approved for Metastatic Colorectal Cancer - about 1 year ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - about 1 year ago Randomized Trial Backs HIF-2a Inhibition in Advanced RCC - about 1 year ago

Journalists covering alectinib